---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-038882"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:54:24.168734+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch

## Summary
- Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.
- Net proceeds expected ~$282M after underwriting discounts and expenses; closing on or about April 6, 2026.
- Underwriters granted 30-day option to purchase up to an additional 1,551,750 shares (15%).
- Proceeds to fund commercial readiness and launch of barzolvolimab for CSU (if approved), clinical/preclinical development, and bispecific platform.
- Lead managers include Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor.

## SEC filing metadata
- accession: 0001104659-26-038882
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/0001104659-26-038882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/tm267111d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-038882
- JSON: https://secwatch.observer/filing/0001104659-26-038882.json
- Plain text: https://secwatch.observer/filing/0001104659-26-038882.txt

## Source-grounded claims
- claim_id: e0e722020817e720b94117a79467f58e9fa4e93e
  claim: Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters valued at approximately $282 million (effective 2026-04-01).
  evidence_excerpt: On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/0001104659-26-038882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.